Zacks: ESSA Pharma Inc. (EPIX) Given Consensus Recommendation of “Buy” by Analysts

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has earned a consensus broker rating score of 1.67 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.

Brokers have set a 12-month consensus target price of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 158 out of 265 based on the ratings given to its competitors.

EPIX has been the topic of several analyst reports. Zacks Investment Research cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th.

Shares of ESSA Pharma (EPIX) traded up $0.02 during trading hours on Friday, reaching $0.23. 11,700 shares of the company’s stock traded hands, compared to its average volume of 27,550. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of -1.32. ESSA Pharma has a 52-week low of $0.15 and a 52-week high of $3.59. The company has a market cap of $6.69, a PE ratio of -1.44 and a beta of 2.09.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/05/zacks-essa-pharma-inc-epix-given-consensus-recommendation-of-buy-by-analysts.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply